ArticleCancers2020

PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.

Foteinos-Ioannis Dimitrakopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.